Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up

Oncotarget

Volumn 7, Issue 41, 2016, Pages 67435-67448

  Critelli, Rossana ^a   Fasanelli, Francesca ^b   Oderda, Marco ^c   Polidoro, Silvia ^a   Assumma, Manuela Bianca ^a   Viberti, Clara ^a,b   Preto, Mirko ^c   Gontero, Paolo ^c   Cucchiarale, Giuseppina ^d   Lurkin, Irene ^e   Zwarthoff, Ellen C ^e   Vineis, Paolo ^a,f   Sacerdote, Carlotta ^g   Matullo, Giuseppe ^a,b   Naccarati, Alessio ^a  

^a Human Genetics Foundation   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Erasmus MC ^*  (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g Centre for Cancer Prevention (CPO Piemonte)   (Italy)

Author keywords

Bladder cancer; Recurrence; TERT; Urine mutation analyses

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; RAS PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL LINE; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FGFR3 GENE; FOLLOW UP; GENETIC SCREENING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; MUTATIONAL ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; ONCOGENE; ONCOGENE RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PIK3CA GENE; PROMOTER REGION; PROSPECTIVE STUDY; TERT GENE; URINARY EXFOLIATED CELL; URINE SAMPLING; AREA UNDER THE CURVE; BLADDER TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; MIDDLE AGED; MUTATION; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; URINE;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84993929548     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11883     Document Type: Article

References (47)

1. Guillaume L, Guy L. [Epidemiology of and risk factors for bladder cancer and for urothelial tumors]. Rev Prat. 2014; 64:1372-1374, 1378-1380.
2. Eble J.N. SG, Epstein J.I., Sesterhenn I.A. (Eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 2004; IARC Press.
3. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013; 63:234-241.
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49:466-465; discussion 475-467.
5. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016.
6. Dancik GM, Owens CR, Iczkowski KA, Theodorescu D. A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells. 2014; 32:974-982.
7. Anastasiadis A, Cordeiro E, Bus MT, Alivizatos G, de la Rosette JJ, de Reijke TM. Follow-up procedures for non-muscle-invasive bladder cancer: an update. Expert Rev Anticancer Ther. 2012; 12:1229-1241.
8. Wang QY, Zhao Y, Zhang R. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer. Minerva Med. 2015; 106:333-337.
9. Cappellen D, De Oliveira C, Ricol D, de Medina SGD, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23:18-20.
10. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 2009; 28:305-316.
11. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28:1075-1083.
12. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010; 5:e13821.
13. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005; 5:713-725.
14. Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2011; 42:455-481.
15. Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol. 2012; 9:41-51.
16. Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, Hemminki K, Kumar R. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer. 2015; 137:1621-1629.
17. Bell RJ, Rube HT, Xavier-Magalhaes A, Costa BM, Mancini A, Song JS, Costello JF. Understanding TERT Promoter Mutations: A Common Path to Immortality. Mol Cancer Res. 2016; 14:315-323.
18. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339:959-961.
19. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015; 347:1006-1010.
20. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013; 110:17426-17431.
21. Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci. 2014; 51:200-231.
22. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014; 65:360-366.
23. Sanguedolce F, Bufo P, Carrieri G, Cormio L. Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci. 2014; 51:291-304.
24. Hurst CD, Platt FM, Knowles MA. Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine. Eur Urol. 2014; 65:367-369.
25. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC, Zwarthoff EC. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003; 21:1912-1921.
26. Ward DG, Baxter L, Gordon NS, Ott S, Savage RS, Beggs AD, James JD, Lickiss J, Green S, Wallis Y, Wei W, James ND, Zeegers MP, Cheng KK, Mathews GM, Patel P, et al. Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS One. 2016; 11:e0149756.
27. Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, Hemminki K, Kumar R. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. International journal of cancer. 2015; 137:1621-1629.
28. Nordentoft I, Lamy P, Birkenkamp-Demtroder K, Shumansky K, Vang S, Hornshoj H, Juul M, Villesen P, Hedegaard J, Roth A, Thorsen K, Hoyer S, Borre M, Reinert T, Fristrup N, Dyrskjot L, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 2014; 7:1649-1663.
29. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013; 12:1637-1638.
30. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, Zwarthoff EC. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010; 16:3011-3018.
31. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA, Jr., Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013; 73:7162-7167.
32. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol. 2014; 65:367-369.
33. Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, Ge N, Liu J, Wang C, Ren H, Yan K, Hu S, Xu Z, Fan Y, Xu D. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Oncologist. 2015; 20:263-269.
34. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Orntoft TF. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 2005; 11:7709-7719.
35. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012; 187:310-314.
36. Sapre N, Anderson PD, Costello AJ, Hovens CM, Corcoran NM. Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? Urol Oncol. 2014; 32:48 e49-17.
37. Tracey E, Watt H, Currow D, Young J, Armstrong B. Investigation of poorer bladder cancer survival in women in NSW, Australia: a data linkage study. BJU Int. 2014; 113:437-448.
38. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol. 2016; 69:300-310.
39. Sanchez-Carbayo M. Urine epigenomics: a promising path for bladder cancer diagnostics. Expert Rev Mol Diagn. 2012; 12:429-432.
40. Kompier LC, van der Aa MN, Lurkin I, Vermeij M, Kirkels WJ, Bangma CH, van der Kwast TH, Zwarthoff EC. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol. 2009; 218:104-112.
41. Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014; 24:487-491.
42. Mbeutcha A, Lucca I, Mathieu R, Lotan Y, Shariat SF. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. Urol Clin North Am. 2016; 43:47-62.
43. Birkenkamp-Demtroder K, Nordentoft I, Christensen E, Hoyer S, Reinert T, Vang S, Borre M, Agerbaek M, Jensen JB, Orntoft TF, Dyrskjot L. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. Eur Urol. 2016.
44. Matullo G, Naccarati A, Pardini B. microRNA expression profiling in bladder cancer: The challenge of Next Generation Sequencing in tissues and biofluids. Int J Cancer. 2015.
45. Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, Orntoft TF, Zwarthoff EC. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J Urol. 2013; 189:1945-1951.
46. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22:1435-1448.
47. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005; 11:7743-7748.